SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Prana Biotechnology Ltd – ‘NT 20-F’ for 10/31/14

On:  Friday, 10/31/14, at 4:59pm ET   ·   Effective:  10/31/14   ·   For:  10/31/14   ·   Accession #:  910662-14-186   ·   File #:  0-49843

Previous ‘NT 20-F’:  ‘NT 20-F’ on 1/2/03 for 6/30/02   ·   Latest ‘NT 20-F’:  This Filing

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

10/31/14  Prana Biotechnology Ltd           NT 20-F    10/31/14    1:39K                                    Carter Ledya… Milburn/FA

Notice of a Late Filing of a Form 20-F   —   Form 12b-25
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: NT 20-F     Fye 6/30/14                                         HTML     28K 


This is an HTML Document rendered as filed.  [ Alternative Formats ]



 C:   C:   C: 



 
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
 
FORM 12b-25
NOTIFICATION OF LATE FILING
 
 
OMB APPROVAL
 
 
OMB Number: 3235-0058
Estimated average burden
hours per response 2.50
 
 
SEC FILE NUMBER
 
 
 
(Check One)   * Form 10-KT Form 20-F  *Form 11-K   * Form 10-Q  * Form 10-D  *  Form N-SAR*  Form N-CSR
CUSIP NUMBER
 
For Period Ended:    June 30, 2014
   Transition Report on Form 10-K
          Transition Report on Form 20-F
          Transition Report on Form 11-K
          Transition Report on Form 10-Q
          Transition Report on Form N-SAR
                     For the Transition Period Ended: _________________________________
 
 
 
Read Instruction (on back page) Before Preparing Form.  Please Print or Type.
   Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
 
If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
 
PART I – REGISTRANT INFORMATION
 
Prana Biotechnology Ltd.
Full Name of Registrant
 
N/A
Former Name if Applicable
 
Level 2, 369 Royal Parade
Address of Principal Executive Office (Street and Number)
 
Parkville, Victoria 3052 Australia
City, State and Zip Code
 
PART II – RULES 12b-25(b) AND (c)
 
If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed.  (Check box if appropriate)
 
 
 
 
 
 
 
[X]
 
(a)The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
[X]
(b)The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
 
(c)The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
 
Persons who are to respond to the collections of information contained in this form are not required to respond unless the form displaysa currently valid OMB control number.
SEC 1344 (04-09)
 
 
 

 

 
PART III – NARRATIVE
State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.
 
The delay in filing the Registrant’s Annual Report on Form 20-F for the year ended June 30, 2014 is due to an unexpected difficulty in EDGARizing all of the exhibits required to be filed in a timely manner.
 

PART IV – OTHER INFORMATION
 
(1)    Name and telephone number of person to contact in regard to this notification
 
Geoffrey P. Kempler      +61 3 9349 4906
(Name)(Area Code)     (Telephone Number)
 
(2)   Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Registrant Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed?  If answer is no, identify report(s).
 
[X ] Yes                                 [  ] No

(3)   Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
[X] Yes                                 [  ] No
 
The Registrant incurred a loss of A$13,329,239 in the year ended June 30, 2014 as compared to a loss of A$7,787,242 in the year ended June 30, 2013.
 
If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
 
The principal reason for the increased loss is that net research and development expenses increased to A$14,908,098 for the year ended June 30, 2014 from A$8,203,822 for the year ended June 30, 2013, an increase of A$6,704,276, or 81.72%.
 
        
 
 
 
Prana Biotechnology Ltd.
 (Name of Registrant as Specified in Charter)
 
has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.
 
Date: October 31, 2014                 By:  /s/Geoffrey P. Kempler
                                                                                                                      Chief Executive Officer
 
 
 
INSTRUCTION: The form may be signed by an executive officer of the Registrant or by any other duly authorized representative.  The name and title of the person signing the form shall be typed or printed beneath the signature.  If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative’s authority to sign on behalf of the registrant shall be filed with the form.
 
ATTENTION
Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).
 
 
 
 
 
GENERAL INSTRUCTIONS
 

1.  
This form is required by Rule 12b-25 (17 CFR 240.12b-25) of the General Rules and Regulations under the Securities Exchange Act of 1934.
2.  
One signed original and four conformed copies of this form and amendments thereto must be completed and filed with the Securities and Exchange Commission, Washington, D.C. 20549, in accordance with Rule 0-3 of the General Rules and Regulations under the Act.  The information contained in or filed with the form will be made a matter of public record in the Commission files.
3.  
A manually signed copy of the form and amendments thereto shall be filed with each national securities exchange on which any class of securities of the registrant is registered.
4.  
Amendments to the notifications must also be filed on form 12b-25 but need not restate information that has been correctly furnished.  The form shall be clearly identified as an amended notification.
5.  
Electronic Filers.  This form shall not be used by electronic filers unable to timely file a report solely due to electronic difficulties.  Filers unable to submit a report within the time period prescribed due to difficulties in electronic filing should comply with either Rule 201 or Rule 202 of Regulation S-T (§232.201 or §232.202 of this chapter) or apply for an adjustment in filing date pursuant to Rule 13(b) of Regulation S-T (§232.13(b) of this chapter).
6.  
Interactive data submissions. This form shall not be used by electronic filers with respect to the submission or posting of an Interactive Data File (§232.11 of this chapter). Electronic filers unable to submit or post an Interactive Data File within the time period prescribed should comply with either Rule 201 or 202 of Regulation S-T (§232.201 and §232.202 of this chapter).

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘NT 20-F’ Filing    Date    Other Filings
8/31/15
Filed on / Effective on / For Period End:10/31/14
6/30/1420-F
6/30/1320-F
 List all Filings 
Top
Filing Submission 0000910662-14-000186   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Thu., Mar. 28, 5:19:43.1am ET